Key Clinical Updates with HER2-Targeting Therapies - Episode 7

Treatment of HER2-Low and Future Therapies in Metastatic Breast Cancer

November 25, 2025

Neil M. Iyengar, MD, Kelly E. McCann, MD, PhD, Kamel Abou Hussein, MD, William J. Gradishar, MD, Sara A. Hurvitz, MD, FACP

Panelists discuss how HER2-low and HER3-directed therapies are expanding precision treatment opportunities in metastatic breast cancer.

EP. 1: Background Information on Targeted Therapies in Breast Cancer

EP. 2: Clinical Trial Evidence for HER2-Targeted Therapies in Early Breast Cancer

EP. 3: The Role of ADCs in Different Subgroups

EP. 4: First-Line Treatment Regimens in Metastatic HER2+ Breast Cancer

EP. 5: Treatment Sequencing in Later Lines of Therapy in HER2+ Metastatic Breast Cancer

EP. 6: Additional Data with HER2-Targeted Agents in Metastatic Breast Cancer

Now Viewing

EP. 7: Treatment of HER2-Low and Future Therapies in Metastatic Breast Cancer

EP. 8: Disease State Information on TNBC

EP. 9: Exciting New Data for TNBC Therapies

EP. 10: Unmet Needs and Future Outlook for HER2-Targeted Therapies

Panelists discuss how:
HER2-low metastatic breast cancer represents a rapidly advancing treatment area, with novel ADCsantibody-drug conjugates driving paradigm shifts. The conversation centers on how these agents—by leveraging potent payload delivery—offer survival benefits previously unseen in this population. They examine HER3-directed therapies as an emerging frontier, considering their mechanistic rationale and early clinical trial outcomes. The experts discuss the expanding biomarker continuum that is blurring traditional HER2 categories and enabling personalized therapy strategies.